Summit Therapeutics Inc (NASDAQ: SMMT) has seen a decline in its stock price by -11.60 in relation to its previous close of 24.39. However, the company has experienced a -26.87% decline in its stock price over the last five trading sessions. fool.com reported 2024-09-22 that This biotech has skyrocketed in value since January. It owes its performance to a potential billion-dollar cancer drug.
Is It Worth Investing in Summit Therapeutics Inc (NASDAQ: SMMT) Right Now?
Company’s 36-month beta value is -1.01.Analysts have differing opinions on the stock, with 3 analysts rating it as a “buy,” 3 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for SMMT is 102.27M, and currently, short sellers hold a 17.83% ratio of that floaft. The average trading volume of SMMT on September 23, 2024 was 4.54M shares.
SMMT’s Market Performance
SMMT’s stock has seen a -26.87% decrease for the week, with a 59.47% rise in the past month and a 169.50% gain in the past quarter. The volatility ratio for the week is 12.23%, and the volatility levels for the past 30 days are at 12.38% for Summit Therapeutics Inc The simple moving average for the past 20 days is 13.45% for SMMT’s stock, with a 210.70% simple moving average for the past 200 days.
Analysts’ Opinion of SMMT
Many brokerage firms have already submitted their reports for SMMT stocks, with H.C. Wainwright repeating the rating for SMMT by listing it as a “Buy.” The predicted price for SMMT in the upcoming period, according to H.C. Wainwright is $16 based on the research report published on August 12, 2024 of the current year 2024.
Citigroup, on the other hand, stated in their research note that they expect to see SMMT reach a price target of $7. The rating they have provided for SMMT stocks is “Buy” according to the report published on May 07th, 2024.
Stifel gave a rating of “Buy” to SMMT, setting the target price at $8 in the report published on March 26th of the current year.
SMMT Trading at 54.29% from the 50-Day Moving Average
After a stumble in the market that brought SMMT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -36.38% of loss for the given period.
Volatility was left at 12.38%, however, over the last 30 days, the volatility rate increased by 12.23%, as shares surge +71.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +161.89% upper at present.
During the last 5 trading sessions, SMMT fell by -24.05%, which changed the moving average for the period of 200-days by +810.21% in comparison to the 20-day moving average, which settled at $19.47. In addition, Summit Therapeutics Inc saw 726.05% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at SMMT starting from Zanganeh Mahkam, who purchase 54,321 shares at the price of $3.72 back on Mar 27 ’24. After this action, Zanganeh Mahkam now owns 24,923,800 shares of Summit Therapeutics Inc, valued at $201,874 using the latest closing price.
Zanganeh Mahkam, the Chief Executive Officer of Summit Therapeutics Inc, purchase 30,000 shares at $3.75 during a trade that took place back on Mar 26 ’24, which means that Zanganeh Mahkam is holding 30,000 shares at $112,500 based on the most recent closing price.
Stock Fundamentals for SMMT
Current profitability levels for the company are sitting at:
- 523.84 for the present operating margin
- 6.32 for the gross margin
The net margin for Summit Therapeutics Inc stands at 688.06. The total capital return value is set at -0.61. Equity return is now at value -102.79, with -55.84 for asset returns.
Based on Summit Therapeutics Inc (SMMT), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at -0.9. The debt to equity ratio resting at 0.56. The interest coverage ratio of the stock is -10.4.
Currently, EBITDA for the company is -87.69 million with net debt to EBITDA at -0.67. When we switch over and look at the enterprise to sales, we see a ratio of -66403.15. The receivables turnover for the company is -0.25for trailing twelve months and the total asset turnover is -0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.35.
Conclusion
In a nutshell, Summit Therapeutics Inc (SMMT) has experienced a better performance in recent times. The stock has received mixed “buy” and “hold” ratings from analysts. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
